Project Grant R44NS120748
- Vulintus, Inc. was awarded a $1,025,456 Project Grant from the National Institute of Neurological Disorders and Stroke within the Department of Health and Human Services to develop the SensiTrak system. The grant was funded under the 21st Century Cures Act Brain Research through Advancing Innovative Neurotechnologies program. Under this award, Vulintus will create an automated, high-throughput behavioral testing platform to precisely measure somatosensory function in rodent models. Current...
- Federal Project Grant Award Summary Tactorum Inc. received a $305,000 Phase I Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), effective January 15, 2026, with completion targeted for December 31, 2026. The project focuses on developing an automated pain behavior testing system designed for preclinical rodent pain research models. The proposed system aims to replace the...
- This $549,195 Project Grant, awarded April 1, 2025, by the National Science Foundation (NSF) Division of Chemical, Bioengineering, Environmental, and Transport Systems under the Engineering program (CFDA 47.041), supports the development of a minimally invasive implantable optical tactile sensor designed to restore somatosensory feedback for patients with paralysis from stroke or spinal cord injury. The University of Pennsylvania will deliver an implantable wireless device that uses...
- This federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $303,000 to Saint Louis University to develop a small animal tensiometer for noninvasively measuring in vivo muscle forces and to evaluate the effectiveness of electrically stimulated eccentric contraction (ESEC) training on improving muscle function following volumetric muscle loss (VML) injury in a rodent model. The...
- Federal Project Grant Award Summary Biosensics LLC received a $2.13M Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded September 1, 2025, with completion targeted for August 31, 2027. The company is developing and validating HDwear, a wearable sensor platform designed to enable continuous, objective monitoring of motor impairment in individuals with Huntington's Disease (HD) and prodromal HD. This technology addresses significant limitations...
- Federal Cooperative Agreement Summary Sentire Medical Systems, Inc. received a $1,189,332 Small Business Technology Transfer (STTR) Phase II Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), awarded June 15, 2025, with a completion date of May 31, 2027. The awardee is developing an intraoperative monitoring device utilizing gas-based sensing technology to detect inadvertent bowel injuries during minimally...
- This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...
- Carolina Instruments, Inc. received a $789,416 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded September 8, 2025, with completion targeted for September 7, 2026. The company is developing a novel Biometric Ocular Photometry (BOP) system designed to simultaneously measure multiple physiological indicators—including pupil size, heart rate, and respiratory rate—in freely moving mice using photoplethysmography...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,505,537 to The Leland Stanford Junior University to develop a focused ultrasound (FUS) device for noninvasive, peripheral nerve blockade to manage acute pain. The goal is to provide an alternative to opioids and current peripheral nerve block techniques, which have significant limitations in acute pain management. The...
- This $275,000 SBIR Phase I Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a wearable multimodal sensing device by Skywalk Inc., a for-profit Asian-Pacific American-owned manufacturer. The device aims to enable more intuitive interaction with augmented reality (AR) technologies by turning human hands into cursors, turning any surface into a touchscreen, and unlocking new...
SENSITRAK: AUTOMATED ASSESSMENT OF FORELIMB SENSATION - PROJECT ABSTRACT CURRENT COMMON METHODS FOR MEASURING SOMATOSENSORY FUNCTION IN PRECLINICAL RODENT MODELS GENERALLY RELY ON WITHDRAWAL RESPONSES TO UNCOMFORTABLE OR PAINFUL STIMULI. THESE TESTS CAN BE STRESSFUL TO THE ANIMAL, WHILE ALSO YIELDING A HIGH VARIABILITY IN MEASURED RESPONSES, AND REPETITIVE TESTING IN LONGITUDINAL MODELS MAY EVEN RESULT IN CHRONIC PAIN STATES. TO BETTER UNDERSTAND THE CONNECTION BETWEEN PHYSIOLOGY AND PERCEPTION OF TOUCH AND PROPRIOCEPTION, RESEARCHERS NEED A MODERN, OFF-THE-SHELF ASSESSMENT SYSTEM TO ADMINISTER AND QUANTIFY TRAINED, VOLITIONAL BEHAVIORS. UNDER THIS PHASE II STTR PROJECT, VULINTUS, INC. WILL CONTINUE TO DEVELOP AND VALIDATE 'SENSITRAK,' AN AUTOMATED, HIGH-THROUGHPUT BEHAVIORAL SYSTEM DESIGNED TO FINELY MEASURE SOMATOSENSORY FUNCTION IN RODENT MODELS. SENSITRAK MEETS THE NEEDS OF SOMATOSENSORY-FOCUSED RESEARCHERS BY SUPPORTING COMPLEX, ELECTROMECHANICAL FEEDBACK INTERACTIONS WITH ANIMALS, WITH INTERCHANGEABLE TASK MODULES, BEHAVIORAL PERIPHERALS, AND OPEN-SOURCE CONTROL SOFTWARE. VULINTUS' PHASE II ACTIVITIES INCLUDED FINALIZATION AND CERTIFICATION OF A COMMON CONTROLLER AND MODULES FOR ASSESSING TACTILE, VIBRATION, AND PROPRIOCEPTION DISCRIMINATION THRESHOLDS. CONCURRENTLY, SENSITRAK SYSTEMS WILL UNDERGO BETA TESTING AT TWO DIFFERENT LABORATORIES AT COLUMBIA UNIVERSITY AND THE WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE. BETA TESTING WILL HELP ESTABLISH THE RELIABILITY AND UTILITY OF SENSITRAK ASSESSMENTS AND WILL GUIDE THE DEVELOPMENT OF PROTOCOLS FOR OTHER LABORATORIES TO FOLLOW WHEN ADOPTING SENSITRAK IN THEIR RESEARCH. AT THE CONCLUSION OF THIS PHASE II, A FULLY DEVELOPED SENSITRAK PRODUCT LINE WILL PROVIDE RESEARCHERS WITH UNPRECEDENTED CAPABILITIES TO RELIABLY MEASURE TACTILE AND PROPRIOCEPTIVE FUNCTION IN EARLY PRECLINICAL ANIMAL MODELS, AND WILL HELP TO IMPROVE THE RATE OF SUCCESSFUL TRANSLATION OF PROMISING THERAPIES FROM PRECLINICAL INVESTIGATIONS TO CLINICAL PRACTICE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/16/25 | ||
| Not listed | $905.6k | 5/30/24 | ||
| Not listed | $0 | 9/20/23 | ||
| Not listed | $0 | 9/20/23 | ||
| Not listed | $982.2k | 6/2/23 |